FURTHER EVALUATION OF THE PROGNOSTIC VALUE OF MORPHOMETRIC AND FLOW CYTOMETRIC PARAMETERS IN BREAST-CANCER PATIENTS WITH LONG FOLLOW-UP

被引:92
|
作者
UYTERLINDE, AM
BAAK, JPA
SCHIPPER, NW
PETERSE, H
MATZE, E
MEIJER, CJL
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS
[2] ANTONI VAN LEEUWENHOEK HOSP,1066 CX AMSTERDAM,NETHERLANDS
关键词
D O I
10.1002/ijc.2910450102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The added prognostic value of cellular DNA content compared with single and combined morphometric factors and classical parameters such as tumor size, nodal status, histologic grade and estrogen receptor (ER) content was investigated in 225 consecutive breast‐cancer patients with long follow‐up. Of all features investigated, the MPI (multivariate prognostic index) had the strongest prognostic value [Mantel‐Cox (MC) =48.2, p <0.00005]. The results further showed that neither age nor ER content had significant prognostic value, but the DNA index (DI) as a single parameter had (though weak) prognostic significance (MC =5.9, p =0.015); a similar result was obtained with the percentage of S‐phase cells (MC =6.1, p =0.013). The DI had (restricted) additional prognostic value to the morphometric features (MPI plus DI Mantel‐Cox 53.0, p <0.0001). The percentage of S‐phase cells had no additional prognostic value over the MPI. On the other hand, the additional value of the DI over tumor size and nodal status was much more impressive (MC =41.0 and 40.7), although it did not reach the prognostic significance of the MPI. Prediction of disease outcome with a linear combination of quantitative microscopical parameters of the primary tumor alone [MAI (mitotic activity index), DI and mean nuclear area] was very accurate, even without considering lymph‐node status (MC 30.8, p <0.0005). Grade had no additional value to the MPI at all (p =0.76). This could be especially important for lymph‐node‐negative patients in whom the prognostic value of the MPI and the MAI are confirmed. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] PREOPERATIVE AND FOLLOW-UP PROCEDURES ON PATIENTS WITH BREAST-CANCER
    SCANLON, EF
    OVIEDO, MA
    CUNNINGHAM, MP
    CAPRINI, JA
    KHANDEKAR, JD
    COHEN, E
    ROBINSON, B
    STEIN, E
    CANCER, 1980, 46 (04) : 977 - 979
  • [22] BREAST-CANCER IN MOTHERS PRESCRIBED DIETHYLSTILBESTROL IN PREGNANCY - FURTHER FOLLOW-UP
    COLTON, T
    GREENBERG, ER
    NOLLER, K
    RESSEGUIE, L
    VANBENNEKOM, C
    HEEREN, T
    ZHANG, YQ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (16): : 2096 - 2100
  • [23] BIOCHEMICAL PARAMETERS FOR PROGNOSTIC EVALUATION IN PATIENTS WITH BREAST-CANCER
    GION, M
    MIONE, R
    PAPPAGALLO, GL
    GATTI, C
    NASCIMBEN, O
    SAMPOGNARO, E
    MEO, S
    ANTICANCER RESEARCH, 1994, 14 (2B) : 693 - 698
  • [24] THE CHANGING IMPORTANCE OF PROGNOSTIC FACTORS IN BREAST-CANCER DURING LONG-TERM FOLLOW-UP
    LIPPONEN, P
    AALTOMAA, S
    ESKELINEN, M
    KOSMA, VM
    MARIN, S
    SYRJANEN, K
    INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (05) : 698 - 702
  • [25] FOLLOW-UP OF BREAST-CANCER CASES
    WOLNIK, L
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1978, 103 (48) : 1895 - 1896
  • [26] FOLLOW-UP CARE FOR BREAST-CANCER
    TRAMS, G
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1991, 250 (1-4) : 267 - 273
  • [27] FOLLOW-UP EXAMINATIONS IN BREAST-CANCER
    ZIELINSKI, C
    RAUSCH, P
    STULLER, I
    KUBISTA, E
    SALZER, H
    STAFFEN, A
    AIGINGER, P
    WIENER KLINISCHE WOCHENSCHRIFT, 1987, 99 (14) : 512 - 512
  • [28] BREAST-CANCER - FOLLOW-UP BY MRI
    BUTHIAU, D
    RIXE, O
    NIZRI, D
    PIETTE, JC
    KHAYAT, D
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 1995, 179 (03): : 693 - 705
  • [29] RESPONSE TO FOLLOW-UP OF BREAST-CANCER
    HIETANEN, P
    STRAHLENTHERAPIE, 1985, 161 (11) : 678 - 680
  • [30] VALUE OF BONE SCANNING IN THE FOLLOW-UP OF BREAST-CANCER PATIENTS - A STUDY OF 1000 CASES
    SCHUNEMANN, H
    LANGECKER, PJ
    ELLGAS, W
    LEONHARDT, A
    MERKL, H
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (05) : 486 - 491